Shots:
- Biocytogen & BeOne have entered into a global licensing agreement for multiple fully human antibodies discovered using Biocytogen’s RenMicefully human antibody platform
- As per the deal, Biocytogen will receive an upfront payment, development, regulatory, & commercial milestones, with net sales-based tiered royalties on licensed products. Although, financial terms remain undisclosed
- Collaboration builds on BeOne Medicines & Biocytogen’s prior agreement to licence RenMice fully human antibody platform, with the new agreement expanding into antibody licensing
Ref: Businesswire | Image: Biocytogen & BeOne | Press Release
Related News:- HealthBook+ Launches PaiGE for Real-Time Personalized Health Insights
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
